Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

RSS icon
Thumbnail

FDA fast-tracks heart failure medication omecamtiv mecarbil

Omecamtiv mecarbil, a cardiac myosin activator being manufactured by Amgen and Cytokinetics to treat heart failure with reduced ejection fraction, has been granted a Fast Track designation by the FDA.

Thumbnail

Rheumatoid arthritis associated with greater risk of HF, especially when CRP levels are high

Rheumatoid arthritis is associated with a greater risk of heart failure, according to new findings published in the Journal of the American Heart Association. The risk increases even more when patients have higher levels of C-reactive protein, a telltale sign of severe inflammation.  

Thumbnail

Mavacamten shows potential for treating hypertrophic cardiomyopathy in EXPLORER-HCM trial

Mavacamten has demonstrated value as a treatment option for patients with obstructive hypertrophic cardiomyopathy (HCM), according to results from the EXPLORER-HCM phase III clinical trial.

Thumbnail

FDA approves Farxiga for HF patients with reduced ejection fraction

The FDA has approved a new treatment option, Farxiga oral tablets, for adult heart failure patients with reduced ejection fraction.

Thumbnail

TTVR improves outcomes for patients with severe tricuspid regurgitation

Transcatheter edge-to-edge tricuspid valve repair (TTVR) is an effective treatment option for patients with severe tricuspid regurgitation (TR), according to a new study published in JACC: Heart Failure.

Thumbnail

Statins reduce risk of developing HF from breast cancer therapies

Key chemotherapy treatments are known to have a negative impact on cardiovascular health, even leading to heart failure (HF) in some patients.

Thumbnail

HF patients with type 2 diabetes can safely be treated with liraglutide

Liraglutide, a common medication used to treat type 2 diabetes (T2D), is safe to use for heart failure (HF) patients, according to new findings published in the Journal of the American College of Cardiology.

Thumbnail

Heart-failure patients lose years of life when air pollution is a neighbor

Long-term daily exposure to air pollution carrying fine particulate matter poses a significant risk of all-cause mortality for people with heart failure (HF).

Displaying 449 - 456 of 1270

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.